(
out of
129
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Research North
Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Internal Medicine (Sub: Hematology)
|
Patient Rating
5.0
/5
( out of
129 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Professor (Clinical) |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Sub: Hematology)
|
Education history
| Undergraduate | Biochemistry - Wichita State University | B.A. |
|---|---|---|
| Professional Dental | Osteopathic Medicine - Kansas City University of Medicine and Biosciences, College of Osteopathic Medicine | D.O. |
| Residency | Internal Medicine - Johns Hopkins University School of Medicine | Resident |
| Fellowship | Hematology/Oncology - University of Tennessee Health Science Center | Fellow |
| Fellowship | Hematology/Oncology - University of Tennessee Health Science Center | Chief Fellow |
Selected Publications
Journal Article
- Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M (2017). Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol, 92(9), E529-E533.
- Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15¿years: A systematic review. Am J Hematol, 96(6), 690-697.
- Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency.(Epub ahead of print). J Cancer Educ.
- Santiago V, Lazaryan A, McClune B, McKenna RW, Courville EL (2018). Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome. Leuk Lymphoma, 59(4), 958-966.
- Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395.
- Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V (2017). Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant, 52(5), 697-703.
- Fair C, Shanley R, Rogosheske J, Lazaryan A, McClune B, Brunstein CG, Bachanova V (2017). BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications. Bone Marrow Transplant, 52(3), 491-493.
- Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ (2013). Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant, 48(11), 1444-9.
- Przepiorka D, Buadi F, McClune B, Franz G, Walsh W, White F (2007). Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 40(8), 759-64.
- McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, Majhail NS (2011). Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant, 46(1), 1-9.
- Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ (2012). Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant, 47(4), 494-8.
- Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577.
- Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426.
- McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S (2010). Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol, 28(11), 1878-87.
- Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402.
- McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-81.
- Bossart A, McClune B, Barrell K, Warner J, Majersik JJ (2021). Pearls & Oy-sters: POEMS Syndrome: An Eloquent Acronym for a Rare Disease You Don't Want to Miss. Neurology, 97(17), 835-838.
- Przepiorka D, Buadi FK, McClune B (2008). Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy, 28(1), 58-63.
- McClune B, Majhail NS, Flowers ME (2012). Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol, 49(1), 59-65.
- Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA (2015). Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res, 21(6), 1267-72.
- McClune BL, Weisdorf DJ (2010). Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Curr Opin Hematol, 17(2), 133-8.
- He F, Cao Q, Lazaryan A, Brunstein C, Holtan S, Warlick E, Ustun C, McClune B, Arora M, Rashidi A, Eckfeldt C, Weisdorf DJ, Bejanyan N (2017). Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. Biol Blood Marrow Transplant, 23(9), 1485-1490.
- Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation. (2014). Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(8), 1183-9.
- McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ (2014). Allotransplantation for patients age ¿40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant, 20(7), 960-8.
- Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ (2011). Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant, 17(7), 1025-32.
- Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE (2009). Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant, 15(2), 214-22.
- Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339.
- Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21(1), 730.
- McClune BL, Majhail NS (2013). Osteoporosis after stem cell transplantation. Curr Osteoporos Rep, 11(4), 305-10.
- Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah AO (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(7), 489-496.
- Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL (2017). Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 4(9), e431-e442.
- Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune B (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol, 7(10), e704-e706.
- Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2021). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304.
- Mohyuddin GR, Abdallah AO, McClune B (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA Oncol, 7(4), 635.
- Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM (2019). Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv, 3(6), 875-883.
- Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2021). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101.
- Steinbach M, Julian K, McClune B, Sborov D. (2022). Toxicity management Strategies for Next Generation Novel Therapeutics in Multiple Myeloma. Ther Adv Hematol, In Press.
- Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 2(4): 74.
- Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167:152-160.
- Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31:9636897221080385.
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V. (2022). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer (1965), 56:164-174.
- Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160.
- Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74.
- Barth D, Singleton M, Monohan G, McClune B, Adams V (2022). Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. Cell Transplant, 31, 9636897221080385.
- Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer, 156, 164-174.
- Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59.
- McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565.
- Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719.
- Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48.
- Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol, 200(5), 587-594.
- McCarthy PL,Owzar K,Hofmeister CC,Hurd DD,Hassoun H,Richardson PG,Giralt S,Stadtmauer EA,Weisdorf DJ,Vij R,Moreb JS,Callander NS,Van Besien K,Gentile T,Isola L,Maziarz RT,Gabriel DA,Bashey A,Landau H,Martin T,Qazilbash MH,Levitan D,McClune B,Schlossman R,Hars V,Postiglione J,Jiang C,Bennett E,Barry S,Bressler L,Kelly M,Seiler M,Rosenbaum C,Hari P,Pasquini MC,Horowitz MM,Shea TC,Devine SM,Anderson KC,Linker C (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med, 366(19), 1770-1781.
- Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 64(7), 1-4.
- Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 65(9), 1-4.
- Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin GR (2025). The Past, Present and Future of Myeloma Staging and Risk Prognostication. Oncologist, 30(10).
- Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin GR (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291.
- Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ERS (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma.(Epub ahead of print) JCO Oncol Pract, OP2500322.
- Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark W, Rapoport AP, Rodriguez TE, Winters JN, Davis M, Miao HM, Ray M, Fang X, Kim JJ, Oluwole OO (2025). Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis. Am J Cancer Res, 15(8), 3417-3433.
- Koehne G, Mushtaq MU, Muffly LS, Menes M, Azzi J, Bernard L, Cooper B, Kennedy V, Koura D, Maakaron J, Magenau J, McClune B, Patel SS, Rimando JC, Shah NN, Suh HC, Tamari R, Thosar S, Canesin G, Hyzy SL, Lee-Sundlov MM, Stanizzi DA, Hummel D, Lin MI, Raffel GD, Whangbo JS, DiPersio JF (2025). Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33). JCO Precis Oncol, 9, e2500556.
Review
- Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659.
- Steinbach M,Julian K,McClune B,Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13.
- Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24, (1), 15-22.
- Odstrcil Bobillo MS, McClune B, Couriel DR (2025). Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US. [Review]. Leuk Lymphoma, 1-11.
Book Chapter
- McClune BL (2014). Clinical Considerations in Myeloma Care. In Plasma Cell Neoplasms. Springer.
- McClune BL (2014). Blood versus Marrow Allogeneic Stem Cell Transplantation. In Lazarus HM, Laughlin, MJ (Eds.), Allogeneic Stem Cell Transplantation: Clinical Research Practice (2nd Edition, pp. 281-97). Humana Press.
- McClune BL (2015). Plasma cell neoplasms, a therapeutic approach. In McClune BL (Ed.), Plasma Cell Neoplasms: A Morphologic, Cytogenetic and Immunophenotypic Approach (pp. 123-141).
Letter
- McClune BL, Defor T, Brunstein C, Vogel RI, Majhail NS, Bachanova V, Burns LJ, Slungaard A, Weisdorf DJ (2012). Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. [Letter to the editor]. Br J Haematol, 156(2), 273-5.
- McClune B, Buadi FK, Aslam N, Przepiorka D (2007). Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. [Letter to the editor]. Leuk Lymphoma, 48(9), 1849-51.
- Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762.
- Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522.
- Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2021). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760.
- Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256.
- Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2021). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621.
- Gil K,Abbasi S,Mehta K,McClune B,Sborov D,Ahmed N,Abdallah AO,Ganguly S,McGuirk J,Shune L,Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59.
Abstract
- Stadtmauer EA, Pasquini MC, Blackwell B, Knust K, Bashey A, Devine SM, Efebera YA, Ganguly S,Gasparetto C, Geller N, Giralt SA,Hari PH, Horowitz MH, Koreth J,Landau H, McCarthy P, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A (2016). Comparison of Autologous Hematopoietic Cell Transplant (auto HCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Auto Hct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial) [Abstract]. Blood, 128, LBA1.
- Shune L, Weisdorf DJ, McClune B, et al (2009). Allogeneic hematopoietic cell transplant for multiple myeloma: Comparative results of planned therapy versus salvage therapy [Abstract]. J Clin Oncol, 27(15s), suppl; abstract 7035.
- McClune B, Burns L, Defor T, Slungaard A, Bachanova V, Brunstein B, Weisdorf D (2009). Hematopoietic cell transplantation for chronic lymphocytic leukemia: similar efficacy of non- myeloablative and myeloablative conditioning; long-term evaluation from the University of Minnesota [Abstract]. Blood, 114, abstract 3385.
- Waheed S, McClune B, Buadi F, Wright K, Przepiorka D (2006 (June 20 Supplement)). The effect of changes in the treatment paradigm for chronic lymphocytic leukemia: A tumor registry study [Abstract]. ASCO Annual Meeting Proceedings Part I, 24(18S), 16000.
- Crenshaw C, Brenner S, McClune B, Bradley R, Przepiorka D (2006). In vivo validation of single platform measurement of CD34 in peripheral blood stem cells [Abstract]. Cytotherapy, 8, 54.
- Buadi F, McClune B, Hull Y, Yunus F, Minhas S, Przepiorka D (2005). The addition of rituximab to standard high dose BEAM chemotherapy for autologous stem cell transplant in patients with lymphoma does have a significant effect on engraftment [Abstract]. Blood, 106, 5325.
- McClune B, Buadi F, Hull Y, Yunus F, Minhas S, Walsh W, Przepiorka D (2005). The natural history of relapse after transplantation for myeloma [Abstract]. Blood, 106, 5511.
- McClune B, Kumar B, Buadi F, Womeodu R, Wright K, Baskin R, Minhas S, Ratliff TW, Spiers K, Yunus F, Przepiorka D (2004). African Americans and Caucasians with myeloma have similar outcomes in the current era: A tumor registry study [Abstract]. Blood, 104, abstract 857.
- Buadi F, McClune B, Moore Y, Womeodu R, Yunus F, Walsh W, Minhas S, Przepiorka D (2004). Race has no effect on survival in multiple myeloma patients undergoing autologous stem cell transplantation [poster presentation also given at American Society of Hematology Annual Meeting, San Diego CA] [Abstract]. Blood, 104, abstract 357.
I love Dr. McClune's care! And importantly, I trust him and his judgement
Dr. McClune is very soft spoken
He is the best!! He follows up on my care, explains test results in detail, listens to concerns, truly cares about his patients. Thorough, always pleasant and is an amazing doctor.
Dr. McClune seems very caring and was able to spend a long period of time answering our questions.
Excellent doctor! He was very thorough & caring. I felt that he really knew about multiple myeloma cared about my outcome.
Kind,caring!!! Never makes you feel rushed, regardless of how many question's you have. I absolutely love him & have total faith in him to get me thru this cancer/stem cell transplant journey
Knowledgeable, caring. Honestly made cancer less frightening.
Dr. McClune and the BMT staff are some of the most competent and caring medical professionals I have ever had the pleasure of working with. Coming to HCI for my cancer treatment had been one of the best choices I have ever made. Thank you for 17 years of your loving care.
Dr. Mcclune is very knowledgeable and caring about his patients.
Excellent discussion of my options and risks and benefits.
Great doctor and cares a great deal about his patients
Dr. McClune is one of the most personable, empathetic and informative physicians I've ever met.He took the trouble during my visit to discuss my issues over the phone with my son, who holds an MD
Good experience
My experiences with Dr. McClune are always excellent. I greatly appreciate his bedside manner.
Dr. McClune is wonderful, he is caring, explains test results. Answers questions and concerns. He is an amazing doctor.
Good experience
good
Good experience
Good
Dr. McClune is a fabulous physician. Knowledgeable, caring, interested and so kind. I feel most fortunate to be under his care.
Everyone was friendly, professional and caring.
Very caring attitude
Dr. McClune is an absolutely awesome doctor! He is very knowledgeable and was very thorough in questioning me, and in the labs he had me get before my appointment. I have been sick and unable to work for TEN YEARS. I have been trying to get diagnosed for a decade now, to now avail. Until Now! Dr. McClune has now diagnosed me with Multiple Myeloma (likely). I get the bone marrow biopsy next week. My cardiologist, Dr. Catino, sent me to Dr. McClune and I will forever be grateful to both of these doctors. After ten years of NO doctors being able to diagnose me, even though I have had cancer markers, Dr. McClune took the time to read through my HUGE chart and put the pieces together. Dr. McClune is very good and much appreciated by me. Oh, and he is friendly, too!
A little hard to understand on iPad's speakers.
Dr McClune is Great
Dr. Mcclune is caring and thorough about all aspects of my disease and recovery process. He is a wonderful provider!
Dr. McClune has educated me on my specific condition and the current options available to treat them. I feel informed regarding my treatment and treatment goals as a result. I also feel that he truly cares about my case and my care.
Dr. McClune is so kind and gentle. He treats me like I'm his favorite person!
He is such a great Doctor! Brilliant in what he does in the Multiple Myeloma Field¿..glad he is in my corner!!!
Dr. Mcclune is very through, made sure I understood the things he was talking about even though they were things that were hard to understand. Made sure tests he ordered were done soon. He seems to really care about his patients.
Dr. McClune listens to my concerns and answers my questions. He is wonderful about reviewing my progress and what my care plan involves going forward. Caring and compassionate!
Good experience
Excellent Dr and staff - very capable
He clearly explained that status of my MUGS and M-protein.
Good experience
Dr. McClune is a very caring physician. When he is with his patients, he makes them feel like he is completely with them and listens to their every word. Something extremely important in his line of work.
Excellent caring
My hematologist blood cancer doctor Dr McClune always exceeds my expectations. He is better than my past doctors at Mayo Clinic!
I really like and appreciate Dr. McClune.
I just have no words to describe how good he was, I tell my friends how grate of a doctor he is.
good
Dr McClune was very thorough in explaining the pros and cons for the new medication I'll be starting.
Dr.McClune and his nurse Steven are amazing. There are not enough words to describe...
Dr McClune is so nice and truly cares about me as a patient. Great and very kind doctor and friend
Dr McClune is a very incredible human and doctor. I never feel like he's in a hurry to get to the next patient. He makes me feel like I am the most important part of his day. I like the way he explains everything so I completely understand the issue. I will always recommend him to anyone looking for a multiple myeloma specialist.
Dr. McClune is great! Listens well and has good responses to questions. And has great socks!!
Dr. McClune has shown kindness, professionalism and genuine compassion. He has treated me with a level of care as if I were his own family. Thru my entire experience at Huntsman, Dr. McClune has encouraged me and treated me with heartfelt kindness and respect, while keeping me informed in a way I can understand.
He's an excellent doctor, very experienced and very kind. He tries to identify the problem. He's very professional. [TRANSLATED]
Dr. McClune is caring and personable. He listens to my concerns and involves me in my treatment plan. Wonderful provider!!
Hes incredibly knowledgeable, great care, takes time with my concerns.
Great doctor!
Su atencion. Es excelente sus palabras algunas no son claras
I cant say enough about how great he wasintelligent, compassionate and warm. He was able to convey difficult material to me in a way that didnt feel condescending or over my head. I also did not feel judged or uncomfortable by anything I had to share with him. I feel very comfortable under his care.
I feel very comfortable with Dr. McClune...always makes me feel at ease, with my Medical Issues.
Dr McClune is very thorough and explains very well what is going on with your medical condition
I would highly recommend Dr McClune!
He was very thorough and explained things in way that I could understand.
Doctor McClune was extremely detailed as we went over my labs. I did not feel rushed at all. He spent approximately one hour answering my questions and explaining his answers in a way I could understand.
Care provided was excellent
So grateful for the opportunity to come to Huntsman for my care. is so important to me. Wonderful care and people.
Dr. McClune was excellent. He explained things in detail and also is a very good listener.
Dr McClune is top notch Oncologist. Super care!!!
Very informative and patient when discussing options and procedures. Took plenty of time with explaining procedures pros and cons.
Dr. McClune provided BMT information in language that I understood while involving me in the conversation and answering my questions. He is good at anticipating questions and was caring. He had his team there for further information and consultation.
He is awesome. Very caring, explains results in detail. Friendly, wonderful person.
He is a wonderful doc and explains things to you in a way you. Understand
Very knowledgeable and among the best, right up there with the Mayo Clinic!
Very helpful and went above and beyond to help.Great Dr.
Dr McClune is the best there is. I feel so fortunate hes my dr.
He was quite generous with his time and explained all the tests so that I could follow his logic. I feel he was sympathetic to my reluctance to have multiple testing done.
Dr. McClune treats patients with respect and explains thing very well.
Love my doctor
Dr. McClune carefully explained the ins and outs of my stem cell transplant and the likely side effects and outcome.
wonderful
Excellent communication respectful, friendly professional and took the time needed to answer my questions and explain treatment options.
Good
Dr. McClune is not only a great physician, but he has a wonderful bedside manner, as well. I really appreciate that he goes above & beyond most physicians, to help find out what is going on with me, medically speaking.
Good experience
Good experience
I have trust in Dr. McClune. He knows his information. He is able to explain things in a ways that the patient can understand. He takes his time with the patient and will answer every question the patient has. You don't feel rushed through the appointment.
He is a very caring professional!
Dr. McClune goes over all test results so I understand what is happening. We discuss options and he involves me in my treatment plan.
We appreciate Dr McClune. Very thorough.
Dr McClune is my favorite doctor. He's thorough, kind and answers all my questions.
Dr. McClune is wonderful and truly cares about patients and their wellbeing. I'm so thankful for him as my oncologist.
Dr. McClune's care and expertise are absolutely top notch.
Dr. McClune is caring and works tirelessly to provide my best care. He explains everything so I understand my plan of care!
I think Dr. McClune is gentle, kind and considerate. He patiently answers my many questions.
Terrific doctor!
Doctor McClune has been nothing but informative and respectful. Hes goes out of his way to keep me educated and he also helps keep me calm when I get ahead of myself.
Absolutely wonderful physician. And VERY thorough and thoughtful
I thought he was very thorough in his answers
He is the of the most caring and wonderful doctors that I have ever met
Good experience
Dr McClune is an excellent physician. He is caring and provides his full attention during each appointment. I consider myself very fortunate to have had the opportunity to be served by Huntsman Cancer Institute for my Leukemia and Bone Marrow Transplant.
Dr. McClune explained my test results to me in detail and answered all my questions. I am very happy with him.
I always do
great
Love him as I have all four doctors who have looked after me since my arrival at the Huntsman in the fall of 2010. Very competent and very kind hearted. I am extremely grateful to him.
Dr. McClune is an excellent doctor and I would highly recommend him. He has helped my battle with myeloma be as comfortable as possible. I know that he has my best interests at heart and I trust my life with him!
Great physician and truly cares about his patients. He makes sure they're getting the care they need.
Everyone is so kind and nice. Thank you. You are all angels
Good careing doctor
Dr. Mcclune treats me like my case is the of the upmost importance. He analyzes every test result and makes sure that all concerns are addressed. He personally called and referred me to a secondary specialist to run needed tests. When all test results are in, he will schedule a follow up to discuss the results.
Kind and competent, Dr. McClune provides shared decision-making in healthcare choices. I trust him and know he is my advocate.
Very good doctor
Dr McClune is a caring and very thorough physician. I'm so glad I have him as my doctor.
Dr. McClune is great!
Dr. McClune was very professional and straightforward.
Dr Mcclune has helped my husband so much. He really cares and listens to all of our concerns. He and his staff are very knowledgeable.
My husband, and I are very confident with my journey with cancer because of the outstanding care I have received!
Dr McClune spent a considerable amount of time explaining the process to us and listening to all of our concerns and questions.
Dr. McClune could not be more attentive. So thorough with his explanations. Most kind and personable. Feel fortunate to be under his care.
He is the best person to guide us through this journey over the last year.
Dr. McCllune and his nurse were very thorough and made me feel very comfortable
all seriousness, he's a great doctor.
Dr.McClune is amazing. He's very thorough. He's an amazing healer as he treats you as a whole person looking at your life and what treatments options are going to help you continue to do the things that you love.
Dr. McClune was genuinely interested in my situation. Attention to details and questions was appreciated. I
Dr came off as an asset to the hospital and left you feeling he had a genuine interest in your care and condition he took the time with his patient to make you feel you had an exultant Dr and staff on your side
Great experience and great doctor.
Thank you Dr McClune and staff
Brian McClune is a very caring doctor and he listens to his patients.
Dr. Mcclune has been great
He is a very patient and excellent oncologist. The translator and all the staff were very kind. Thank you for your service. [TRANSLATED]
Great doctor, very professional and truly cares about his patients.
Dr. McClune listened to my concerns and answered my questions. He is thorough with planning.
He is a caring, listening professional whom I trust.
Dr McClune is an outstanding doctor treating my blood cancer. Hes been very effective in halting the cancer and improving my health. He is better than my prior doctors at Mayo Clinic. Highly recommend Dr. McClune.
Dr McClune is so kind, his care is exceptional.
included everything!
Concerned dedicated staff through out
I have had an excellent experience with Dr. Brian McClune throughout my AML and transplant experience. He is an excellent physician and always puts his patients firsts.
Brian checks all the boxes on what you would want from a doctor. We work together as a team on all aspects of my treatment. Most important he cares about the life I am living from all the hardwork put behind us.
Very caring
So grateful for the wonderful help provided by all of the staff and Doctor.
Dr McClune explained my blood and Urine numbers in a way that was easy to understand. We both agreed on the best treatment plan.
I was amazed at the care that he took to make sure I understood everything. I have never had better care
Dr. McClune is thorough and caring.
Dr. McClune, is not only an amazing doctor but a wonderful person. He is so caring and easy to talk to. Makes you feel assured, truly cares for his patients.
Kind, professional and very direct and respectful!
Absolutely the best doctor for multiple myeloma.
I felt at home with Dr McClune
Thank you for being kind, compassionate, thorough and straightforward. Thank you forctaking the time to discuss mt Healthcare at great length and in understandable language. And thank you for answering all of mt questions.
He is not only exceptionally skilled in his specialty, he is also very caring.